RNA transfection

Touchlight Signs Patent License Agreement With Pfizer for the Use of dbDNA for the Manufacture of mRNA-based Vaccines, Therapeutics and Gene Therapies

Retrieved on: 
Wednesday, July 6, 2022
Biotechnology, Pharmaceutical, Genetics, Health, Therapy, Escherichia coli, Biotechnology, GMP, RNA transfection, Technology, RNA, Gene, DNA, Pharmaceutical industry, Vaccine, TouchLight, Pfizer

Touchlight , a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a non-exclusive patent license agreement with Pfizer.

Key Points: 
  • Touchlight , a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a non-exclusive patent license agreement with Pfizer.
  • Under the license agreement, Pfizer gains rights to Touchlights enzymatic doggybone DNA (dbDNA) patent portfolio for worldwide use in Pfizers manufacture and commercialisation of its messenger RNA-based vaccines, therapeutics and gene therapies.
  • Touchlights patented dbDNA technology produces a minimal, linear, double stranded, covalently closed DNA vector through an enzymatic manufacturing process.
  • dbDNA is uniquely positioned for the rapid, synthetic, and scalable manufacture of GMP DNA using a small, simple footprint.

PharmaJet Presents Multiple Partners’ Data Demonstrating Superior Immunogenicity With Their Needle-free Systems at BIO International Convention

Retrieved on: 
Tuesday, July 5, 2022
Science, Biotechnology, Research, Pharmaceutical, Medical Supplies, General Health, Health, Medical Devices, Review, Therapy, Injection, III, RNA transfection, MS, Research, Feedback, INRA, Plasmid, COVID-19, Electroporation, II, Jab, Public health, MBA, Publication, DNA, Use, Vaccine

The presentation, entitled Improved Vaccine and Therapeutic Performancewithout the Jab, was presented by Paul LaBarre, MS, MBA, Vice President Global Business Development at PharmaJet, Inc.

Key Points: 
  • The presentation, entitled Improved Vaccine and Therapeutic Performancewithout the Jab, was presented by Paul LaBarre, MS, MBA, Vice President Global Business Development at PharmaJet, Inc.
  • There is a growing body of evidence that shows needle-free delivery can make injectables perform better.
  • Currently there are 18 partner publications that show equivalent or better effectiveness when using the PharmaJet NFIS compared with either electroporation or traditional needle and syringe.
  • Refer to Instructions for Use to ensure safe injections and to review risks.

Billion-Euro Market Biotechnology: Exyte Builds mRNA Competence Center for WACKER in Halle

Retrieved on: 
Tuesday, July 5, 2022
Cell, Semiconductor, RNA transfection, CEO, Biotechnology, Engineering, Nature, Research, Therapy, Construction, Pandemic, Program, Growth, Cancer, OECD, Industry, Food, Life expectancy, Automation, Wacker Chemie, Center, List of life sciences, Diet, Quality of life, EUR, Government, Vaccine, Safety, BCG, Pharmaceutical industry, Fine chemical, Health, Biopharma LLC, Exyte

STUTTGART, Germany, July 5, 2022 /PRNewswire/ --Exyte GmbH (Exyte), a global leader in the design, engineering and delivery of facilities for high-tech industries, is building a mRNA competence center at the Halle Biotech site of Wacker Chemie AG (WACKER).

Key Points: 
  • STUTTGART, Germany, July 5, 2022 /PRNewswire/ --Exyte GmbH (Exyte), a global leader in the design, engineering and delivery of facilities for high-tech industries, is building a mRNA competence center at the Halle Biotech site of Wacker Chemie AG (WACKER).
  • The WACKER Group concentrates its biopharmaceuticals activities within Wacker Biotech, a full-service provider for microbial manufacturing of pharmaceutical proteins.
  • At the new competence center, WACKER will manufacture active ingredients based on messenger ribonucleic acid (mRNA) used in coronavirus vaccines and in medicinal products for the treatment of cancer amongst others.
  • We are making an important contribution towards producing cutting-edge mRNA therapeutics, both for personalized medicine and for the mass market, and are thus driving medical progress," says Dr. Wolfgang Bchele, CEO of Exyte.

DGAP-News: CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech

Retrieved on: 
Tuesday, July 5, 2022
RNA transfection, Protein, Achievement, GSK, Invention, BioNTech, Engineering, DE, COVID-19, Sale, Degenerative disease, Public health, Judiciary, CureVac, Infection, Technology, RNA, CVAC, Nasdaq, Vaccine, SARS, U1, Pfizer

CureVac does not seek an injunction nor intend to take legal action that impedes the production, sale or distribution of Comirnaty by BioNTech and its partner Pfizer.

Key Points: 
  • CureVac does not seek an injunction nor intend to take legal action that impedes the production, sale or distribution of Comirnaty by BioNTech and its partner Pfizer.
  • The CureVac intellectual property portfolio protects multiple inventions that are considered essential to the design and development of BioNTechs SARS CoV-2 mRNA vaccine, among others.
  • CureVac considers the rapid development of these vaccines a tremendous achievement, with unprecedented positive impact for global public health.
  • This achievement is based on decades of scientific research and innovation, supported by CureVac as the earliest pioneer in mRNA technology.

Oligonucleotide Synthesis, Modification, and Purification Services Market worth $6.53 Billion by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Tuesday, July 5, 2022
GE Healthcare, Integrated DNA Technologies, Medication, Research, NGS, Hospital, COVID-19, Growth, Uridine, Diagnosis, Mass spectrometry, Vaccine, Molecular biology, Lists of diseases, Oligonucleotide, RNA transfection, Integration, CMOS, GMP, Thermo Fisher Scientific, Dharmacon, CAGR, RNA, Mirna, Contract, SNP, Biotechnology, Wuxi, LC, Viral Research and Diagnostic Laboratories, Merck Millipore, University of Sheffield, Sheffield, PCR, Degenerative disease, Nucleotide, CDMO, OEM, Bio-Synthesis, Inc., University, Biochemistry, DNA, Regulus Therapeutics, Medicine, Uridine triphosphate, Agilent Technologies, Fine chemical

Ltd. announces the release of a market assessment report on the " Global Oligonucleotide Synthesis, Modification and Purification Services Market Oligonucleotide Mfg.

Key Points: 
  • Ltd. announces the release of a market assessment report on the " Global Oligonucleotide Synthesis, Modification and Purification Services Market Oligonucleotide Mfg.
  • According to the latest research by InsightAce Analytic, the global oligonucleotide synthesis, modification, and purification services market is valued at US$ 1.56 billion in 2021, and it is expected to reach US$ 6.53 billion by 2030 with a CAGR of 17.50% during a forecast period of 2022-30.
  • Recently, there has been an augmented interest in involving modified oligoribonucleotides in molecular biology, biochemistry, and medicine.
  • However, the high expenses for the purification process, complex manufacturing procedures, oligo-degradation in the generic research, in-house development of oligonucleotides may hinder the growth of the global oligonucleotide synthesis, modification, and purification services market.

SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China

Retrieved on: 
Monday, July 4, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Department, Pharmacy and Poisons Board, Pharmacy, Influenza A virus subtype H1N1, School, Admission, CEO, RNA transfection, Adult, Research, GHK, Trial of the century, Polio, Li Ka Shing Faculty of Medicine, Wong Chuk Hang, Infection, COVID-19, Immunization, Â, Sinovac Biotech, Department of Medicine – University of Pamplona, HKU, Omicron, School of Clinical Medicine, University of Cambridge, LKS, Viral hepatitis, Asia-Pacific, Campus Biotech, IHH Healthcare, Poison, Clinical trial, NWS Holdings, University, IRB, Virus, Pyaar Tune Kya Kiya (TV series), Animal, Vaccine, Chickenpox, Safety, University of Hong Kong, Vaccination, EV71, Immunity, Faculty, Mumps, Bed, Multimedia, International business, Volunteering, Pharmaceutical industry, Medicine, Gleneagles Hospital

This study is led by a medical research team of the University of Hong Kong Clinical Trials Centre (HKU-CTC) in collaboration with Gleneagles.

Key Points: 
  • This study is led by a medical research team of the University of Hong Kong Clinical Trials Centre (HKU-CTC) in collaboration with Gleneagles.
  • The University of Hong Kong Clinical Trials Centre (HKU-CTC) is a one-stop clinical research management platform dedicated to facilitating the professional conduct of clinical research projects under HKUMed.
  • As Hong Kongs top-notch private teaching hospital, Gleneagles also contributes to the training and development of healthcare professionals and advancement of clinical research.
  • Gleneagles is a joint venture between IHH Healthcare and NWS Holdings Limited, with The University of Hong Kong as its exclusive clinical partner.

Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine

Retrieved on: 
Wednesday, June 29, 2022
Emergency Use Authorization, Annual report, Science, Hoffmann-La Roche, LinkedIn, RNA transfection, Pfizer–BioNTech COVID-19 vaccine, Peer review, Research, DO, Marketing, COVID-19, Cancer, Company, U.S. Securities and Exchange Commission, Omicron, Regeneron Pharmaceuticals, Pierre Geneves, Awareness, Infection, Publication, Risk, YouTube, Clinical trial, Private Securities Litigation Reform Act, News, SEC, Facebook, BioNTech, Immunotherapy, Vaccine, Government, EUA, Safety, Twitter, Vaccination, Pediatrics, Program, BNT162, Genentech, Pfizer

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer .
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine

Retrieved on: 
Wednesday, June 29, 2022
Biotechnology, General Health, COVID-19, Health, Pharmaceutical, Emergency Use Authorization, Annual report, Science, Hoffmann-La Roche, LinkedIn, RNA transfection, Pfizer–BioNTech COVID-19 vaccine, Peer review, Research, DO, Marketing, COVID-19, Cancer, Company, U.S. Securities and Exchange Commission, Omicron, Regeneron Pharmaceuticals, Pierre Geneves, Awareness, Infection, Publication, Risk, YouTube, Clinical trial, Private Securities Litigation Reform Act, News, SEC, Facebook, BioNTech, Immunotherapy, Vaccine, Government, EUA, Safety, Twitter, Vaccination, Pediatrics, Program, BNT162, Genentech, Pfizer

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer .
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Greater Philadelphia Region Seeks ARPA-H Home

Retrieved on: 
Wednesday, June 29, 2022
Drexel University, Wistar Institute, Bangladesh Technical Education Board, FDA, Chamber, Patient, Coriell Institute for Medical Research, RNA transfection, GSK, Children's Hospital of Philadelphia, HHS, Jefferson Health, Research, Senior, Johnson & Johnson, COVID-19, Commerce, International airport, Atmosphere, ARPA, NIH, PHL, Temple University, Institute for Economic Competitiveness, Letter, DARPA, Hospital, Bristol Myers Squibb, Gene editing, University, AstraZeneca, Congress, Philadelphia International Airport, Vaccine, Intention, Pharmaceutical industry, Merck, Delaware Valley, Pfizer

PHILADELPHIA, June 29, 2022 /PRNewswire/ -- The Chamber of Commerce for Greater Philadelphia today announced the region's intention to seek to be the new home for a recently announced $1 billion federal agency, the Advanced Research Projects Agency for Health (ARPA-H), which is expected to be located outside of Washington D.C.  In a letter sent to the U.S. Health & Human Services Department Secretary Xavier Becerra and signed by business, civic, and elected officials, signers tout the region's expertise in cell & gene therapy and gene editing, its rank as one of the top eight life sciences markets in the U.S., and its deep scientific and medical ecosystem as reasons why this area stands out as the ideal location. The new agency, established by Congress earlier this year, will speed up biomedical and health cures and treatment by funding new and innovative research.

Key Points: 
  • "We feel that Greater Philadelphia's position as a global hub of research, talent, capital, and companies, combined with its second-to-none accessibility, give this region the power to forever transform how care is delivered to patients and essentially cure the incurable," the letter states.
  • "Today the Chamber is launching a multi-state, eleven-county regional effort to attract the new Advanced Research Projects Agency for Health to the Greater Philadelphia region," said Claire Marrazzo Greenwood, Executive Director and Senior Vice President of Economic Competitiveness for the Chamber.
  • The Philadelphia region has a long and deep track record of innovation.
  • To date, six FDA-approved cell & gene therapies have their origins in the region.

HDT Bio’s COVID-19 Vaccine Wins Regulatory Approval in India

Retrieved on: 
Wednesday, June 29, 2022
Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, COVID-19, Temperature, Global health, Vaccine, RNA transfection, Infection, Safety, Technology, RNA, SaRNA, HDT

Indian regulators have issued an Emergency Use Approval for Gemcovac, a groundbreaking COVID-19 vaccine based on the technology of Seattle biotech HDT Bio Corp.

Key Points: 
  • Indian regulators have issued an Emergency Use Approval for Gemcovac, a groundbreaking COVID-19 vaccine based on the technology of Seattle biotech HDT Bio Corp.
  • The vaccine uses self-amplifying RNA (or saRNA), which replicates itself following administration and is thus effective at extremely low doses.
  • Our saRNA vaccine is a game changer, said HDT Bio CEO Steve Reed.
  • HDT Bios vaccine is currently undergoing clinical trials in the U.S., Brazil, and South Korea.